Taking engineered anti-CEA antibodies to the clinic (Q33825200)

29 July 2017

1 reference

title

Taking engineered anti-CEA antibodies to the clinic (English)

1 reference

29 July 2017

Mayer A

1

1 reference

29 July 2017

Chester KA

series ordinal

2

1 reference

29 July 2017

Flynn AA

series ordinal

3

1 reference

29 July 2017

Begent RH

series ordinal

4

1 reference

29 July 2017

publication date

1 December 1999

1 reference

Journal of Immunological Methods

29 July 2017

published in

1 reference

29 July 2017

volume

231

1 reference

29 July 2017

issue

1-2

1 reference

29 July 2017

page(s)

261-273

1 reference

Intraoperative Detection of Colorectal Cancer With Radioimmunoguided Surgery and CC49, a Second-generation Monoclonal Antibody

29 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Liposomally entrapped second antibody improves tumour imaging with radiolabelled (first) antitumour antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Cancer Research Campaign operation manual for control recommendations for products derived from recombinant DNA technology prepared for investigational administration to patients with cancer in phase I trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Purification of bacterially expressed single chain Fv antibodies for clinical applications using metal chelate chromatography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Preparation, characterisation and tumour targeting of cross-linked divalent and trivalent anti-tumour Fab' fragments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Clearance of yttrium-90-labelled anti-tumour antibodies with antibodies raised against the 12N4 DOTA macrocycle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Production and tumour-binding characterization of a chimeric anti-CEA Fab expressed in Escherichia coli.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Phage libraries for generation of clinically useful antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Radioimmunoguided surgery using iodine 125 B72.3 in patients with colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

The value of radioimmunoguided surgery in first and second look laparotomy for colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

A novel technique, using radioluminography, for the measurement of uniformity of radiolabelled antibody distribution in a colorectal cancer xenograft model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Monoclonal antibody administration. Current clinical pharmacokinetic status and future trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Continuous cultures of fused cells secreting antibody of predefined specificity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Targeting strategy for gene delivery to carcinoembryonic antigen-producing cancer cells by retrovirus displaying a single-chain variable fragment antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Radioimmunotherapy of metastatic colorectal tumours with iodine-131-labelled antibody to carcinoembryonic antigen: phase I/II study with comparative biodistribution of intact and F(ab')2 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Clearance of circulating radio-antibodies using streptavidin or second antibodies in a xenograft model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Polyethylene glycol modification of a galactosylated streptavidin clearing agent: effects on immunogenicity and clearance of a biotinylated anti-tumour antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Exemplifying guidelines for preparation of recombinant DNA products in phase I trials in cancer: preparation of a genetically engineered anti-CEA single chain Fv antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

High-affinity antigen binding by chelating recombinant antibodies (CRAbs).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Comparative radioimmunotherapy using intact or F(ab')2 fragments of 131I anti-CEA antibody in a colonic xenograft model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

The potential for enhanced tumour localisation by poly(ethylene glycol) modification of anti-CEA antibody

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Galactosylated antibodies and antibody-enzyme conjugates in antibody-directed enzyme prodrug therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

A single chain Fv derived from a filamentous phage library has distinct tumor targeting advantages over one derived from a hybridoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

Making antibodies by phage display technology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0022-1759%2899%2900162-3

10.1016/S0022-1759(99)00162-3

7 January 2021

Identifiers

DOI

1 reference

29 July 2017

1 reference